9 slides from EKF Diagnostics's earnings presentation, Sep 19, 2018
Slide 1: Financial results for six months ended 30 June 2018
Financial results for six months ended 30 June 2018 19 September 2018
Slide 2: Disclaimer
Disclaimer This presentation is the sole responsibility of the directors of EKF Diagnostics Holdings plc (the “Company”). Nplus1 Singer Advisory LLP (“N+1 Singer”), which is authorised and regulated by the Financial Conduct Authority, is acting as the nominated adviser and broker to the Company. Thi
Slide 3: Agenda
Agenda Slide no. 4. Financial highlights 5. Operational highlights 6. Income statement: Extract 7. Statement of financial position: Extract 8. Outlook
Slide 4: Financial Highlights
Financial Highlights 2012 2013 2014 2015 • Adjusted EBITDA* up 7% to £4.90m (H1 2017: £4.58m) 2016 2017 2018 • Revenues in-line year-on-year on a constant currency basis at £21.20m (H1 2017: £21.50m) • 4.90 Reported revenues of £20.36m, impacted by exchange rates 4.58 • Strong cash generation from o
Slide 5: Operational Highlights
Operational Highlights • DiaSpect Tm has received FDA 510k CLIA clearance • OEM contract with McKesson – Surgical Inc. • Exclusive rights for distribution of DiaSpect Tm in all US markets except blood banks, driving further US sales growth following November 2018 product launch • Substantial revenue
H2 and 2019 Outlook • Growth opportunities from new registrations, new products and customers: – McKesson OEM of DiaSpect Tm. First shipments Q4 2018 – Incremental growth from Life Sciences following capital investment in additional fermenters and strong order book – Launch of Lactate Scout 4.0 in Q